Literature DB >> 14694107

Efficient intracellular assembly of papillomaviral vectors.

Christopher B Buck1, Diana V Pastrana, Douglas R Lowy, John T Schiller.   

Abstract

Although the papillomavirus structural proteins, L1 and L2, can spontaneously coassemble to form virus-like particles, currently available methods for production of L1/L2 particles capable of transducing reporter plasmids into mammalian cells are technically demanding and relatively low-yield. In this report, we describe a simple 293 cell transfection method for efficient intracellular production of papillomaviral-based gene transfer vectors carrying reporter plasmids. Using bovine papillomavirus type 1 (BPV1) and human papillomavirus type 16 as model papillomaviruses, we have developed a system for producing papillomaviral vector stocks with titers of several billion transducing units per milliliter. Production of these vectors requires both L1 and L2, and transduction can be prevented by papillomavirus-neutralizing antibodies. The stocks can be purified by an iodixanol (OptiPrep) gradient centrifugation procedure that is substantially more effective than standard cesium chloride gradient purification. Although earlier data had suggested a potential role for the viral early protein E2, we found that E2 protein expression did not enhance the intracellular production of BPV1 vectors. It was also possible to encapsidate reporter plasmids devoid of BPV1 DNA sequences. BPV1 vector production efficiency was significantly influenced by the size of the target plasmid being packaged. Use of 6-kb target plasmids resulted in BPV1 vector yields that were higher than those with target plasmids closer to the native 7.9-kb size of papillomavirus genomes. The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694107      PMCID: PMC368835          DOI: 10.1128/jvi.78.2.751-757.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  The papillomavirus E2 proteins: structure, function, and biology.

Authors:  Rashmi S Hegde
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001-10-25

Review 2.  Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses.

Authors:  M K Howett; N D Christensen; J W Kreider
Journal:  Clin Dermatol       Date:  1997 Mar-Apr       Impact factor: 3.541

Review 3.  In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences.

Authors:  L T Chow; T R Broker
Journal:  Clin Dermatol       Date:  1997 Mar-Apr       Impact factor: 3.541

4.  Generation and neutralization of pseudovirions of human papillomavirus type 33.

Authors:  F Unckell; R E Streeck; M Sapp
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.

Authors:  W J Liu; L Gissmann; X Y Sun; A Kanjanahaluethai; M Müller; J Doorbar; J Zhou
Journal:  Virology       Date:  1997-01-20       Impact factor: 3.616

6.  trans-activation of RNA polymerase II and III promoters by SV40 small t antigen.

Authors:  M Loeken; I Bikel; D M Livingston; J Brady
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

7.  Factors influencing alternative splice site utilization in vivo.

Authors:  X Y Fu; J L Manley
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

8.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

Authors:  N D Christensen; J Dillner; C Eklund; J J Carter; G C Wipf; C A Reed; N M Cladel; D A Galloway
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

9.  Phosphorylation sites of the E2 transcriptional regulatory proteins of bovine papillomavirus type 1.

Authors:  A A McBride; J B Bolen; P M Howley
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Sequence heterogeneity in closed simian virus 40 deoxyribonucleic acid.

Authors:  H T Tai; C A Smith; P A Sharp; J Vinograd
Journal:  J Virol       Date:  1972-02       Impact factor: 5.103

View more
  283 in total

1.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

3.  Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

Authors:  Cynthia Y Abban; Patricio I Meneses
Journal:  Virology       Date:  2010-05-02       Impact factor: 3.616

4.  Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China.

Authors:  Xue-ling Wu; Chun-tao Zhang; Xiao-ke Zhu; You-chun Wang
Journal:  Virol Sin       Date:  2010-02-12       Impact factor: 4.327

5.  Human papillomaviruses: a growing field.

Authors:  Denise A Galloway
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

6.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

7.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

8.  Human keratinocyte cultures in the investigation of early steps of human papillomavirus infection.

Authors:  Laura M Griffin; Louis Cicchini; Tao Xu; Dohun Pyeon
Journal:  Methods Mol Biol       Date:  2014

9.  A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Authors:  Benjamin D Grant; Chelsey A Smith; Philip E Castle; Michael E Scheurer; Rebecca Richards-Kortum
Journal:  Vaccine       Date:  2016-09-22       Impact factor: 3.641

10.  Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Authors:  Katherine M Johnson; Rhonda C Kines; Jeffrey N Roberts; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.